Skip to main content

Table 1 Description of Patient Demographic Characteristics at the Index Date When SU or TZD Was Added to Prior Metformin Therapy

From: Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary

Characteristic

All Patients

N = 414

SU* + MF

n = 341

TZD** + MF

n = 73

Age (mean yrs ± std)

60.5 ± 9.5

61.0 ± 8.9

57.9 ± 11.3

Female (%)

49.8%

49.0%

53.4%

Current Smokers (%)

13.5%

13.5%

13.7%

Zero alcohol consumption (%)

42.5%

43.1%

39.7%

Absence of Regular Physical Activity (%)

28.0%

28.7%

24.7%

Physical Activity 3–5 Times/Week (%)

11.6%

12.0%

9.6%

Height (mean cm ± std)

168.0 ± 8.7

168.0 ± 8.6

168.6 ± 9.3

Weight (mean kg ± std)

88.7 ± 15.5

88.5 ± 15.5

90.0 ± 15.4

BMI (mean ± std)

31.2 ± 4.7

31.2 ± 4.7

31.5 ± 4.8

H/O Micro-vascular Complications (%)

8.0%

8.5%

5.5%

H/O Macro-vascular Complications (%)

26.5%

25.8%

27.4%

Years since T2DM Diagnosis (mean yrs ± std)

6.6 ± 4.4

6.7 ± 4.4

6.2 ± 4.3

A1C Level (mean A1C ± std)

8.2 ± 1.5

8.3 ± 1.5

7.8 ± 1.2

  1. * SU: Sulfonylurea
  2. MF: Metformin
  3. ** TZD: Thiazolidinedione
  4. H/O: history of